MyFinsight
Home
Blog
About
Short-term investments
available for sale
$375,913K
(-51.42%↓ Y/Y)
Cash and cash
equivalents
$125,750K
(271.16%↑ Y/Y)
Prepaid clinical trial
and preclinical...
$14,960K
(-9.21%↓ Y/Y)
Prepaid expenses and
other current assets
$941K
(-66.57%↓ Y/Y)
Total current assets
$517,564K
(-37.42%↓ Y/Y)
Right-of-use assets
$4,010K
(414.10%↑ Y/Y)
Restricted cash
$211K
Deposits
$113K
(145.65%↑ Y/Y)
Total assets
$521,898K
(-36.96%↓ Y/Y)
Total liabilities and
stockholders equity
$521,898K
(-36.96%↓ Y/Y)
Total stockholders
equity
$408,317K
(-48.67%↓ Y/Y)
Total liabilities
$113,581K
(250.67%↑ Y/Y)
Accumulated deficit
-$1,133,893K
(-89.27%↓ Y/Y)
Accumulated other
comprehensive (loss) gain
-$1,153K
(-594.58%↓ Y/Y)
Additional paid-in capital
$1,543,362K
(10.66%↑ Y/Y)
Total current
liabilities
$109,656K
(242.89%↑ Y/Y)
Total long-term
liabilities
$3,925K
(857.32%↑ Y/Y)
Common stock, 0.00001
par value...
$1K
(0.00%↑ Y/Y)
Accounts payable
$69,012K
(1156.13%↑ Y/Y)
Other accrued
liabilities
$40,483K
(55.60%↑ Y/Y)
Lease liability,
current
$161K
(-65.60%↓ Y/Y)
Lease liability, net
of current portion
$3,925K
(857.32%↑ Y/Y)
Back
Back
Balance Sheet
viking_9_15_logo-svg
Viking Therapeutics, Inc. (VKTX)
viking_9_15_logo-svg
Viking Therapeutics, Inc. (VKTX)
source: myfinsight.com